Literature DB >> 17951305

Chemical reactions of vitamin C with intravenous-iron formulations.

Suxin Wang1, Gina Geraci, Martin K Kuhlmann, Nathan W Levin, Garry J Handelman.   

Abstract

BACKGROUND: Intravenous (IV) iron is widely prescribed for patients on haemodialysis, to replace iron losses during treatment. It releases labile iron, which can induce oxidation of vitamin C and trigger oxidant damage. We examined the stability of vitamin C in the presence of IV iron compounds. We further examined in the ability of vitamin C to release iron from these compounds.
METHODS: Vitamin C was measured by high-performance liquid chromatography with electrochemical detection. Iron release from iron sucrose (FeSuc) and ferric gluconate (FeGlu) was determined with the ferrozine method.
RESULTS: Vitamin C, in human plasma or fetal calf serum, was oxidized in this order of reactivity: FeSuc > FeGlu > blank reaction. FeSuc and FeGlu also oxidized vitamin C when added to freshly obtained whole human blood. During a 4 h incubation in buffer, vitamin C stimulated the release of 60% of the iron content of FeSuc at p 4, with lesser amounts at pH 3, 5 and 6, and 5% release at pH 7. Vitamin C also triggered the release of iron from FeGlu, but less release was observed than with FeSuc. Using ferrozine reagent, no iron release was detected to heparinized human plasma, following addition of 500 microM concentrations of iron compounds.
CONCLUSION: Each IV-iron compound can oxidize substantial amounts of vitamin C when added to plasma or whole blood. The interaction of vitamin C is accompanied by release of iron from the particle at mildly acidic pH, which may explain the ability of high-dose vitamin C to mobilize iron from storage sites for erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951305     DOI: 10.1093/ndt/gfm557

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  In situ chemichromic studies of interactions between a lutetium bis-octaalkyl-substituted phthalocyanine and selected biological cofactors.

Authors:  C Pal; A N Cammidge; M J Cook; J L Sosa-Sanchez; A K Sharma; A K Ray
Journal:  J R Soc Interface       Date:  2011-06-15       Impact factor: 4.118

2.  Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis.

Authors:  Fredric O Finkelstein; Peter Juergensen; Suxin Wang; Sally Santacroce; Mark Levine; Peter Kotanko; Nathan W Levin; Garry J Handelman
Journal:  Perit Dial Int       Date:  2010-06-17       Impact factor: 1.756

Review 3.  Iron and anemia in human biology: a review of mechanisms.

Authors:  Garry J Handelman; Nathan W Levin
Journal:  Heart Fail Rev       Date:  2008-03-25       Impact factor: 4.214

4.  The effect of increased frequency of hemodialysis on vitamin C concentrations: an ancillary study of the randomized Frequent Hemodialysis Network (FHN) daily trial.

Authors:  Jochen G Raimann; Samer R Abbas; Li Liu; Brett Larive; Gerald Beck; Peter Kotanko; Nathan W Levin; Garry Handelman
Journal:  BMC Nephrol       Date:  2019-05-17       Impact factor: 2.388

5.  Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial.

Authors:  Matteo Briguglio; Silvana Hrelia; Marco Malaguti; Elena De Vecchi; Giovanni Lombardi; Giuseppe Banfi; Patrizia Riso; Marisa Porrini; Sergio Romagnoli; Fabio Pino; Tiziano Crespi; Paolo Perazzo
Journal:  Nutrients       Date:  2020-01-31       Impact factor: 5.717

6.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

7.  Ferrous iron content of intravenous iron formulations.

Authors:  Ajay Gupta; Raymond D Pratt; Alvin L Crumbliss
Journal:  Biometals       Date:  2016-03-08       Impact factor: 2.949

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.